Intravenous administration of recombinant human C1-inhibitor (rhC1-INH) has also been demonstrated to be safe and effective in resolving angioedema attacks at a dose of 50 IU/kg for patients weighing <84 kg and 4200 IU for those weighing >84 kg [24]. This evidence concerns the gene SERPING1 and angioedema.